Global glioblastoma market set to reach $1.4 billion by 2027, says analyst

Although the glioblastoma (GBM) treatment market is small with many unmet needs, it is expected to grow from $662.0 million in 2017 to $1.4 billion in 2027 across the eight major markets (8MM) at a compound annual growth rate (CAGR) of 7.5%, according to data and analytics company GlobalData.

The company’s latest report: ‘ Glioblastoma Multiforme (GBM) Opportunity Analysis and Forecasts to 2027’ states that a drive to address the high level of unmet needs will be hindered by difficulties in clinical development, leading to only modest growth in the GBM market.

Ashwin Oberoi, pharma analyst at GlobalData, says: “Clinical trial design for glioblastoma is extremely challenging, many drugs have shown promise in early-stage single arm studies but end up failing in randomized Phase III trials. GBM is considered a disease with some of the highest unmet needs in oncology, where patients have a median overall survival between one and two years.